APA (7th ed.) Citation

Huber, H., Edenhofer, S., von Tresckow, J., Robrecht, S., Zhang, C., Tausch, E., . . . Stilgenbauer, S. (2022). Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 139(9), . https://doi.org/10.1182/blood.2021013208

Chicago Style (17th ed.) Citation

Huber, Henriette, et al. "Obinutuzumab (GA-101), Ibrutinib, and Venetoclax (GIVe) Frontline Treatment for High-risk Chronic Lymphocytic Leukemia." Blood 139, no. 9 (2022). https://doi.org/10.1182/blood.2021013208.

MLA (9th ed.) Citation

Huber, Henriette, et al. "Obinutuzumab (GA-101), Ibrutinib, and Venetoclax (GIVe) Frontline Treatment for High-risk Chronic Lymphocytic Leukemia." Blood, vol. 139, no. 9, 2022, https://doi.org/10.1182/blood.2021013208.